Shield Therapeutics   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Weybridge United Kingdom (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2011
NCT01352221
First Marketed Drug
2019
ferric maltol (Accrufer)
First NDA Approval
2019
ferric maltol (Accrufer)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Phosphate Therapeutics | Shield Therapeutics | SHIELD TX

Active Ingredients

Marketed Drugs (1)

ferric maltol (Accrufer) (2019 NDA)

Drugs in Phase 3 Trials (3)

ferric carboxymaltose (Injectafer) (1 trial)

ferric maltol (Accrufer) (7 trials)

ferrous sulfate (1 trial)

Drugs in Phase 2 Trials (1)

pt20 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Deficiency Diseases (Phase 3)

Hyperphosphatemia (Phase 2)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Kidney Diseases (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4